Cover Image
Market Research Report

Asia Pacific Active Pharmaceutical Ingredients Market Forecast 2019-2027

Published by Inkwood Research Product code 819213
Published Content info 90 Pages
Delivery time: 2-3 business days
Price
Back to Top
Asia Pacific Active Pharmaceutical Ingredients Market Forecast 2019-2027
Published: April 8, 2019 Content info: 90 Pages
Description

KEY FINDINGS

There are various chemicals included in the drugs and the portion that works in treating the condition, i.e., the active part is known as 'Active Pharmaceutical Ingredients' or API in short. While each drug also consists of an excipient part, known as a carrier, it is the API that is considered while prescribing a drug.

The Asia Pacific active pharmaceutical ingredients market is escalating at a significant growth rate of 7.45% CAGR during the forecasting years of 2019-2027. The availability of cheap labor in this densely populated region coupled with the establishment of market players in the developing countries in APAC is expected to drive the market growth.

MARKET INSIGHTS

The economies of China, India, Japan, South Korea, Australia and the remaining countries collectively forming the Rest of Asia Pacific regional segment are the major revenue contributors to the APAC active pharmaceutical ingredients market. The healthcare expenditure in China is projected to reach a huge value soon because the nation shelters the largest population in the world, where there has been a significant rise in chronic conditions such as that of cancer, cardiovascular diseases, diabetes, and obesity, etc. These factors collectively create a huge scope for API market development.

Japan makes up another significantly large market in the Asia Pacific region for the API market. The high rise in geriatric population in the country coupled with higher expectation for an enhanced quality of life will be driving the market demand in the country.

COMPETITIVE INSIGHTS

The major market players operating in the APAC region, which are exhaustively profiled in terms of their adopted market strategies, business segments are Teva Pharmaceutical Industries, Ltd., Merck & Co., Inc., Abbvie, Inc., Cipla, Bristol-Myers Squibb, Dr. Reddy's Laboratories, Sun Pharmaceuticals Industries, Ltd., Mylan N.V., Bayer AG, Eli Lilly and Company, Novartis, Albemarle Corporation, Lonza Group AG, Aurobindo Pharma, and Boehringer Ingelheim GmbH.

Table of Contents
Product Code: 24571

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP-DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. INNOVATIVE APIS HOLDS THE LARGEST MARKET SHARE IN TERMS OF ACTIVE PHARMACEUTICAL INGREDIENTS TYPE
    • 3.2.2. MERCHANT APIS ARE THE FASTEST GROWING MANUFACTURERS
    • 3.2.3. BIOTECH IS THE FASTEST GROWING SYNTHESIS SEGMENT
    • 3.2.4. ONCOLOGY IS THE MAJORLY USED APPLICATION

4. MARKET DYNAMICS

  • 4.1. MARKET SCOPE & DEFINITION
  • 4.2. MARKET DRIVERS
    • 4.2.1. GROWING GERIATRIC POPULATION
    • 4.2.2. GROWING PREVALENCE OF INFECTIOUS DISEASES AND HOSPITAL ACQUIRED INFECTIONS
    • 4.2.3. INCREASING INCIDENCE OF AGE-RELATED DISEASES
  • 4.3. MARKET RESTRAINTS
    • 4.3.1. HIGH COST OF INVESTMENT AND PRODUCTION COST
    • 4.3.2. AGGRESSIVE COMPETITION AMONG API MANUFACTURERS
  • 4.4. MARKET OPPORTUNITIES
    • 4.4.1. GAINING POPULARITY FOR TARGETED THERAPY
    • 4.4.2. GROWING PREFERENCE FOR OUTSOURCING APIS
    • 4.4.3. IMPLEMENTING MEASURES AGAINST COUNTERFEIT DRUGS
  • 4.5. MARKET CHALLENGES
    • 4.5.1. STRINGENT GOVERNMENT REGULATIONS
    • 4.5.2. AVAILABILITY OF COUNTERFEIT PRODUCTS

5. MARKET BY TYPES

  • 5.1. GENERIC APIS
  • 5.2. INNOVATIVE APIS

6. MARKET BY MANUFACTURERS

  • 6.1. CAPTIVE APIS
  • 6.2. MERCHANT APIS

7. MARKET BY SYNTHESIS

  • 7.1. BIOTECH
    • 7.1.1. MONOCLONAL ANTIBODIES
    • 7.1.2. RECOMBINANT PROTEINS
    • 7.1.3. VACCINES
  • 7.2. SYNTHETIC

8. MARKET BY APPLICATION

  • 8.1. CARDIOVASCULAR DISEASE
  • 8.2. ONCOLOGY
  • 8.3. CNS AND NEUROLOGICAL DISORDERS
  • 8.4. ORTHOPEDIC DISORDERS
  • 8.5. ENDOCRINOLOGY
  • 8.6. PULMONOLOGY
  • 8.7. GASTROINTESTINAL DISORDERS
  • 8.8. NEPHROLOGY
  • 8.9. OPHTHALMOLOGY
  • 8.10. OTHER APPLICATION

9. KEY ANALYTICS

  • 9.1. PORTER'S FIVE FORCES MODEL
    • 9.1.1. THREAT OF NEW ENTRANTS
    • 9.1.2. THREAT OF SUBSTITUTE
    • 9.1.3. BARGAINING POWER OF BUYERS
    • 9.1.4. BARGAINING POWER OF SUPPLIERS
    • 9.1.5. THREAT OF COMPETITIVE RIVALRY
  • 9.2. PESTEL ANALYSIS
  • 9.3. SUPPLY CHAIN ANALYSIS
  • 9.4. OPPORTUNITY MATRIX

10. GEOGRAPHICAL ANALYSIS

  • 10.1. ASIA PACIFIC
    • 10.1.1. JAPAN
    • 10.1.2. CHINA
    • 10.1.3. INDIA
    • 10.1.4. AUSTRALIA
    • 10.1.5. SOUTH KOREA
    • 10.1.6. REST OF ASIA PACIFIC

11. COMPETITIVE LANDSCAPE

  • 11.1. MARKET POSITION ANALYSIS
  • 11.2. COMPANY PROFILES
    • 11.2.1. ABBVIE, INC.
    • 11.2.2. ALBEMARLE CORPORATION
    • 11.2.3. AUROBINDO PHARMA
    • 11.2.4. BAYER AG
    • 11.2.5. BOEHRINGER INGELHEIM GMBH
    • 11.2.6. BRISTOL-MYERS SQUIBB
    • 11.2.7. CIPLA
    • 11.2.8. DR. REDDY'S LABORATORIES
    • 11.2.9. ELI LILLY AND COMPANY
    • 11.2.10. LONZA GROUP AG
    • 11.2.11. MERCK & CO., INC.
    • 11.2.12. MYLAN N.V.
    • 11.2.13. NOVARTIS
    • 11.2.14. SUN PHARMACEUTICALS INDUSTRIES, LTD.
    • 11.2.15. TEVA PHARMACEUTICAL INDUSTRIES LTD.

LIST OF TABLES

  • TABLE 1 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • TABLE 2 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPES 2019-2027 ($ MILLION)
  • TABLE 3 ASIA PACIFIC GENERIC APIS MARKET 2019-2027 ($ MILLION)
  • TABLE 4 ASIA PACIFIC INNOVATIVE APIS MARKET 2019-2027 ($ MILLION)
  • TABLE 5 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURERS 2019-2027 ($ MILLION)
  • TABLE 6 ASIA PACIFIC CAPTIVE APIS MARKET 2019-2027 ($ MILLION)
  • TABLE 7 ASIA PACIFIC MERCHANT APIS MARKET 2019-2027 ($ MILLION)
  • TABLE 8 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY SYNTHESIS 2019-2027 ($ MILLION)
  • TABLE 9 ASIA PACIFIC BIOTECH MARKET 2019-2027 ($ MILLION)
  • TABLE 10 ASIA PACIFIC BIOTECH MARKET BY TYPES 2019-2027 ($ MILLION)
  • TABLE 11 ASIA PACIFIC MONOCLONAL ANTIBODIES MARKET 2019-2027 ($ MILLION)
  • TABLE 12 ASIA PACIFIC RECOMBINANT PROTEINS MARKET 2019-2027 ($ MILLION)
  • TABLE 13 ASIA PACIFIC VACCINES MARKET 2019-2027 ($ MILLION)
  • TABLE 14 ASIA PACIFIC SYNTHETIC MARKET 2019-2027 ($ MILLION)
  • TABLE 15 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY APPLICATION 2019-2027 ($ MILLION)
  • TABLE 16 ASIA PACIFIC CARDIOVASCULAR DISEASE MARKET 2019-2027 ($ MILLION)
  • TABLE 17 ASIA PACIFIC ONCOLOGY MARKET 2019-2027 ($ MILLION)
  • TABLE 18 ASIA PACIFIC CNS AND NEUROLOGICAL DISORDERS MARKET 2019-2027 ($ MILLION)
  • TABLE 19 ASIA PACIFIC ORTHOPEDIC DISORDERS MARKET 2019-2027 ($ MILLION)
  • TABLE 20 ASIA PACIFIC ENDOCRINOLOGY MARKET 2019-2027 ($ MILLION)
  • TABLE 21 ASIA PACIFIC PULMONOLOGY MARKET 2019-2027 ($ MILLION)
  • TABLE 22 ASIA PACIFIC GASTROINTESTINAL DISORDERS MARKET 2019-2027 ($ MILLION)
  • TABLE 23 ASIA PACIFIC NEPHROLOGY MARKET 2019-2027 ($ MILLION)
  • TABLE 24 ASIA PACIFIC OPHTHALMOLOGY MARKET 2019-2027 ($ MILLION)
  • TABLE 25 ASIA PACIFIC OTHER APPLICATION MARKET 2019-2027 ($ MILLION)
  • TABLE 26 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • TABLE 27 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 28 ACTIVE PHARMACEUTICAL INGREDIENTS COMPANY MARKET POSITION ANALYSIS 2017

LIST OF FIGURES

  • FIGURE 1 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 2 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY TYPES 2018 & 2027 (%)
  • FIGURE 3 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GENERIC APIS 2019-2027 ($ MILLION)
  • FIGURE 4 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY INNOVATIVE APIS 2019-2027 ($ MILLION)
  • FIGURE 5 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY MANUFACTURERS 2018 & 2027 (%)
  • FIGURE 6 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY CAPTIVE APIS 2019-2027 ($ MILLION)
  • FIGURE 7 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MERCHANT APIS 2019-2027 ($ MILLION)
  • FIGURE 8 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY SYNTHESIS 2017 & 2027 (%)
  • FIGURE 9 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BIOTECH 2019-2027 ($ MILLION)
  • FIGURE 10 ASIA PACIFIC BIOTECH MARKET BY MONOCLONAL ANTIBODIES 2019-2027 ($ MILLION)
  • FIGURE 11 ASIA PACIFIC BIOTECH MARKET BY RECOMBINANT PROTEINS 2019-2027 ($ MILLION)
  • FIGURE 12 ASIA PACIFIC BIOTECH MARKET BY VACCINES 2019-2027 ($ MILLION)
  • FIGURE 13 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY SYNTHETIC 2019-2027 ($ MILLION)
  • FIGURE 14 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY APPLICATION 2018 & 2027 (%)
  • FIGURE 15 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY CARDIOVASCULAR DISEASE 2019-2027 ($ MILLION)
  • FIGURE 16 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY ONCOLOGY 2019-2027 ($ MILLION)
  • FIGURE 17 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY CNS AND NEUROLOGICAL DISORDERS 2019-2027 ($ MILLION)
  • FIGURE 18 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY ORTHOPEDIC DISORDERS 2019-2027 ($ MILLION)
  • FIGURE 19 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY ENDOCRINOLOGY 2019-2027 ($ MILLION)
  • FIGURE 20 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY PULMONOLOGY 2019-2027 ($ MILLION)
  • FIGURE 21 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GASTROINTESTINAL DISORDERS 2019-2027 ($ MILLION)
  • FIGURE 22 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY NEPHROLOGY 2019-2027 ($ MILLION)
  • FIGURE 23 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY OPHTHALMOLOGY 2019-2027 ($ MILLION)
  • FIGURE 24 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY OTHER APPLICATION 2019-2027 ($ MILLION)
  • FIGURE 25 PORTER'S FIVE FORCE MODEL
  • FIGURE 26 ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET REGIONAL OUTLOOK 2018 & 2027 (%)
  • FIGURE 27 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 28 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 29 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 30 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 31 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 32 REST OF ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
Back to Top